|
September 14th, 2005
Chiasma Inc., focused on oral delivery of macromolecule drugs,
has completed $6.2 million Series B financing round. Investors included F-2 Ventures, Ofer Hi-Tech Group, the InnoMed Fund
and Yissum Ltd.
The technology Chiasma is developing has the potential to eliminate
the need for drug injections. According to Dr Dalia Megiddo, managing partner of InnoMed Venture, "Hundreds of Biotechnology
drugs are in development. With current delivery systems, all these new drugs would have to be given by injection. Chiasma
has found the delivery system that will enable, for the first time, oral delivery of these drugs. These are exciting news
for the Biotechnology industry and for hundreds of millions of patients throughout the world. It is clear that Chiasma's potential
is huge."
|
